Athenex Inc (NASDAQ:ATNX)’s share price reached a new 52-week low during trading on Friday . The company traded as low as $13.04 and last traded at $13.20, with a volume of 11888 shares. The stock had previously closed at $13.52.

A number of research firms recently commented on ATNX. ValuEngine lowered shares of Athenex from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. BidaskClub lowered shares of Athenex from a “buy” rating to a “hold” rating in a research report on Thursday, June 28th. Finally, Zacks Investment Research raised shares of Athenex from a “sell” rating to a “hold” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Athenex presently has an average rating of “Hold” and an average price target of $22.75.

The firm has a market cap of $941.28 million, a P/E ratio of -5.79 and a beta of -1.67.

Athenex (NASDAQ:ATNX) last released its earnings results on Tuesday, August 14th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Athenex had a negative net margin of 122.29% and a negative return on equity of 73.37%. The firm had revenue of $11.57 million during the quarter. As a group, sell-side analysts forecast that Athenex Inc will post -2 EPS for the current fiscal year.

In other news, Director Jinn Wu bought 12,500 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were purchased at an average cost of $13.47 per share, with a total value of $168,375.00. Following the acquisition, the director now directly owns 311,208 shares in the company, valued at $4,191,971.76. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Song-Yi Zhang sold 102,734 shares of the firm’s stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $17.24, for a total transaction of $1,771,134.16. Following the completion of the transaction, the director now directly owns 4,000 shares in the company, valued at $68,960. The disclosure for this sale can be found here. Over the last three months, insiders acquired 27,000 shares of company stock worth $405,120 and sold 344,317 shares worth $5,859,972. 29.50% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of ATNX. Schwab Charles Investment Management Inc. boosted its stake in shares of Athenex by 303.9% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 126,323 shares of the company’s stock valued at $2,149,000 after purchasing an additional 95,048 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Athenex by 95.1% in the 1st quarter. Northern Trust Corp now owns 146,236 shares of the company’s stock valued at $2,487,000 after purchasing an additional 71,287 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Athenex by 54.8% in the 1st quarter. BlackRock Inc. now owns 1,683,185 shares of the company’s stock valued at $28,631,000 after purchasing an additional 596,200 shares in the last quarter. A.R.T. Advisors LLC acquired a new stake in shares of Athenex in the 1st quarter valued at approximately $289,000. Finally, Barclays PLC boosted its stake in shares of Athenex by 426.5% in the 1st quarter. Barclays PLC now owns 5,913 shares of the company’s stock valued at $100,000 after purchasing an additional 4,790 shares in the last quarter. Institutional investors own 19.83% of the company’s stock.

Athenex Company Profile (NASDAQ:ATNX)

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Featured Story: Diversification in Investing

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.